{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T03:34:43Z","timestamp":1785641683462,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40120-025-00747-5","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T10:59:25Z","timestamp":1747133965000},"page":"1383-1417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Understanding the Patient Experience of Advanced Parkinson\u2019s Disease: Qualitative Research with Patients and Expert Clinicians to Identify Symptoms and Associated Health-Related Quality of Life Impacts"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1873-5312","authenticated-orcid":false,"given":"Nicola","family":"Williamson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0690-5359","authenticated-orcid":false,"given":"Thomas","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7077-2183","authenticated-orcid":false,"given":"Helena","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife","family":"Lydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-465X","authenticated-orcid":false,"given":"Molly","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8881-1856","authenticated-orcid":false,"given":"Patrick","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1985-8923","authenticated-orcid":false,"given":"Milton","family":"Biagioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"747_CR1","unstructured":"US Food and Drug Administration (FDA). The Voice of the Patient: Parkinson's Disease Public Meeting. 2016."},{"key":"747_CR2","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/480260","volume":"2010","author":"S Varanese","year":"2011","unstructured":"Varanese S, Birnbaum Z, Rossi R, Di Rocco A. Treatment of advanced Parkinson\u2019s disease. Parkinsons Dis. 2011;2010: 480260. https:\/\/doi.org\/10.4061\/2010\/480260.","journal-title":"Parkinsons Dis"},{"key":"747_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.02.001","volume":"51","author":"KL Chou","year":"2018","unstructured":"Chou KL, Stacy M, Simuni T, et al. The spectrum of \u201coff\u201d in Parkinson\u2019s disease: What have we learned over 40 years? Parkinsonism Relat Disord. 2018;51:9\u201316. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.02.001.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"747_CR4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1365-2648.2010.05459.x","volume":"67","author":"A Haahr","year":"2011","unstructured":"Haahr A, Kirkevold M, Hall EO, Ostergaard K. Living with advanced Parkinson\u2019s disease: a constant struggle with unpredictability. J Adv Nurs. 2011;67(2):408\u201317. https:\/\/doi.org\/10.1111\/j.1365-2648.2010.05459.x.","journal-title":"J Adv Nurs"},{"issue":"12","key":"747_CR5","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063\u201373. https:\/\/doi.org\/10.1080\/03007995.2018.1502165.","journal-title":"Curr Med Res Opin"},{"key":"747_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106065","volume":"8","author":"S Aslam","year":"2024","unstructured":"Aslam S, Manfredsson F, Stokes A, Shill H. \u201cAdvanced\u201d Parkinson\u2019s disease: a review. Parkinson Relat Disord. 2024;8: 106065.","journal-title":"Parkinson Relat Disord"},{"issue":"1","key":"747_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40120-021-00313-9","volume":"11","author":"A Antonini","year":"2022","unstructured":"Antonini A, Pahwa R, Odin P, et al. Psychometric properties of clinical indicators for identification and management of advanced Parkinson\u2019s disease: real-world evidence from G7 countries. Neurol Therapy. 2022;11(1):303\u201318.","journal-title":"Neurol Therapy"},{"issue":"1","key":"747_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12883-022-02560-1","volume":"22","author":"IA Malaty","year":"2022","unstructured":"Malaty IA, Martinez-Martin P, Chaudhuri KR, et al. Does the 5\u20132-1 criteria identify patients with advanced Parkinson\u2019s disease? Real-world screening accuracy and burden of 5\u20132-1-positive patients in 7 countries. BMC Neurol. 2022;22(1):35.","journal-title":"BMC Neurol"},{"key":"747_CR9","unstructured":"US Food and Drug Administration (FDA). Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Guidance for Industry. 2009."},{"key":"747_CR10","unstructured":"US Food and Drug Administration (FDA). Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments [Draft Guidance]. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome"},{"key":"747_CR11","unstructured":"US Food and Drug Administration (FDA). Patient-Focused Drug Development: Methods to Identify What Is Important to Patients. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. 2022."},{"key":"747_CR12","unstructured":"US Food and Drug Administration (FDA). Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints For Regulatory Decision-Making: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders (Draft Guidance). 2023."},{"key":"747_CR13","unstructured":"US Food and Drug Administration (FDA). Patient-Focused Drug Development: Collecting Comprehensive and Representative Input. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input"},{"key":"747_CR14","unstructured":"Michael J. Fox Foundation for Parkinson\u2019s Research. Fox Insight publications. https:\/\/foxden.michaeljfox.org\/insight\/explore\/publications.jsp"},{"key":"747_CR15","unstructured":"Friese S. ATLAS.ti 9 Windows https:\/\/doc.atlasti.com\/QuicktourWin.v9\/ATLAS.ti_QuickTourWin.v9.pdf"},{"key":"747_CR16","first-page":"363","volume":"9","author":"T Larsen","year":"1983","unstructured":"Larsen T, LeWitt P, Calne D. Theoretical and practical issues in assessment of deficits and therapy in parkinsonism. Lisuride Dopam Agon. 1983;9:363\u201373.","journal-title":"Lisuride Dopam Agon"},{"key":"747_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"M Hennink","year":"2022","unstructured":"Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: a systematic review of empirical tests. Soc Sci Med. 2022;292: 114523.","journal-title":"Soc Sci Med"},{"issue":"2","key":"747_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"9","key":"747_CR19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"H-F Hsieh","year":"2005","unstructured":"Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388.","journal-title":"Qual Health Res"},{"issue":"3","key":"747_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1586\/erp.10.30","volume":"10","author":"C Kerr","year":"2010","unstructured":"Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):269\u201381.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"747_CR21","unstructured":"Adelphi Real World (ARW). Adelphi real world overview of Parkinson's disease. Chapter 1,2,3,4,5. 2021."},{"key":"747_CR22","unstructured":"Betts M, Yoon S, Chitnis M, Alvarez P. The burden and unmet need in Parkinson's disease: motor and non-motor symptoms. 2021."},{"issue":"1","key":"747_CR23","doi-asserted-by":"publisher","first-page":"9611","DOI":"10.1038\/s41598-021-88651-4","volume":"11","author":"DJ van Wamelen","year":"2021","unstructured":"van Wamelen DJ, Sauerbier A, Leta V, et al. Cross-sectional analysis of the Parkinson\u2019s disease non-motor international longitudinal study baseline non-motor characteristics, geographical distribution and impact on quality of life. Sci Rep. 2021;11(1):9611. https:\/\/doi.org\/10.1038\/s41598-021-88651-4.","journal-title":"Sci Rep"},{"issue":"2","key":"747_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245285","volume":"16","author":"I Lin","year":"2021","unstructured":"Lin I, Edison B, Mantri S, et al. Triggers and alleviating factors for fatigue in Parkinson\u2019s disease. PLoS ONE. 2021;16(2): e0245285. https:\/\/doi.org\/10.1371\/journal.pone.0245285.","journal-title":"PLoS ONE"},{"key":"747_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.prdoa.2019.07.008","volume":"1","author":"MJ Armstrong","year":"2019","unstructured":"Armstrong MJ, Rastgardani T, Gagliardi AR, Marras C. The experience of off periods: qualitative analysis of interviews with persons with Parkinson\u2019s and carepartners. Clin Park Relat Disord. 2019;1:31\u20136. https:\/\/doi.org\/10.1016\/j.prdoa.2019.07.008.","journal-title":"Clin Park Relat Disord"},{"issue":"4","key":"747_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215384","volume":"14","author":"MJ Armstrong","year":"2019","unstructured":"Armstrong MJ, Rastgardani T, Gagliardi AR, Marras C. Barriers and facilitators of communication about off periods in Parkinson\u2019s disease: qualitative analysis of patient, carepartner, and physician Interviews. PLoS ONE. 2019;14(4): e0215384. https:\/\/doi.org\/10.1371\/journal.pone.0215384.","journal-title":"PLoS ONE"},{"issue":"3","key":"747_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/mdc3.12915","volume":"7","author":"LM Chahine","year":"2020","unstructured":"Chahine LM, Edison B, Daeschler M, et al. The most bothersome aspects of off periods reported by individuals with Parkinson\u2019s disease. Mov Disord Clin Pract. 2020;7(3):284\u201392. https:\/\/doi.org\/10.1002\/mdc3.12915.","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"747_CR28","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1212\/cpj.0000000000001059","volume":"11","author":"LM Chahine","year":"2021","unstructured":"Chahine LM, Edison B, Daeschler M, et al. Use of figurative language by people with parkinson disease to describe \u201coff\u201d periods: clear as mud. Neurol Clin Pract. 2021;11(4):e462\u201371. https:\/\/doi.org\/10.1212\/cpj.0000000000001059.","journal-title":"Neurol Clin Pract"},{"issue":"4","key":"747_CR29","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3233\/jpd-150631","volume":"5","author":"MH Nilsson","year":"2015","unstructured":"Nilsson MH, Iwarsson S, Thordardottir B, Haak M. Barriers and facilitators for participation in people with Parkinson\u2019s disease. J Parkinsons Dis. 2015;5(4):983\u201392. https:\/\/doi.org\/10.3233\/jpd-150631.","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"747_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/mdc3.12672","volume":"5","author":"T Rastgardani","year":"2018","unstructured":"Rastgardani T, Armstrong MJ, Gagliardi AR, Marras C. Understanding, impact, and communication of \u201coff\u201d periods in Parkinson\u2019s disease: a scoping review. Mov Disord Clin Pract Sep-Oct. 2018;5(5):461\u201370. https:\/\/doi.org\/10.1002\/mdc3.12672.","journal-title":"Mov Disord Clin Pract Sep-Oct"},{"issue":"1","key":"747_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3233\/jpd-191785","volume":"10","author":"T Rastgardani","year":"2020","unstructured":"Rastgardani T, Armstrong MJ, Gagliardi AR, Grabovsky A, Marras C. Experience and impact of OFF periods in Parkinson\u2019s disease: a survey of physicians, patients, and carepartners. J Parkinsons Dis. 2020;10(1):315\u201324. https:\/\/doi.org\/10.3233\/jpd-191785.","journal-title":"J Parkinsons Dis"},{"key":"747_CR32","unstructured":"Michael J. Fox foundation. Executive summary: survey of parkinson\u2019s patients and their off time experience. New York 2014."},{"key":"747_CR33","unstructured":"Horn S, Coughlin D, Chou J, et al. Patient and provider experiences and attitudes toward Rytary. (suppl 2) ed: International Parkinson and Movement Disorder Society; 2018."},{"issue":"3","key":"747_CR34","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3233\/jpd-202029","volume":"10","author":"S Mantri","year":"2020","unstructured":"Mantri S, Klawson E, Albert S, et al. Understanding the Lexicon of Fatigue in Parkinson\u2019s Disease. J Parkinsons Dis. 2020;10(3):1185\u201393. https:\/\/doi.org\/10.3233\/jpd-202029.","journal-title":"J Parkinsons Dis"},{"key":"747_CR35","unstructured":"US Food and Drug Administration (FDA). CDER Patient-Focused Drug Development. 2022."},{"key":"747_CR36","unstructured":"European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease. 2012."},{"key":"747_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107036","volume":"8","author":"G Donzuso","year":"2024","unstructured":"Donzuso G, Luca A, Cicero C, Mostile G, Nicoletti A, Zappia M. Non-motor symptoms in PD evaluated during pharmacological ON state by a new tool: The NoMoS-ON scale. Is always the\" ON\" state beneficial? Parkinson Relat Disord. 2024;8: 107036.","journal-title":"Parkinson Relat Disord"},{"key":"747_CR38","unstructured":"UK Parkinson's Excellence Network. 2017 UK Parkinson\u2019s Audit - Summary report. 2017. https:\/\/www.parkinsons.org.uk\/sites\/default\/files\/2018-05\/CS2257%20UK%20Parkinson%27s%20Audit%20Summary_Report_FINAL_0.pdf"},{"issue":"1","key":"747_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14737175.2018.1400383","volume":"18","author":"P Martinez-Martin","year":"2018","unstructured":"Martinez-Martin P, Ray CK. Comprehensive grading of Parkinson\u2019s disease using motor and non-motor assessments: addressing a key unmet need. Expert Rev Neurother. 2018;18(1):41\u201350.","journal-title":"Expert Rev Neurother"},{"key":"747_CR40","first-page":"34","volume":"8","author":"R Huelin","year":"2015","unstructured":"Huelin R, Iheanacho I, Payne K, Sandman K. What\u2019s in a name? Systematic and non-systematic literature reviews, and why the distinction matters. The Evidence F\u00f3rum. 2015;8:34\u20137.","journal-title":"The Evidence F\u00f3rum."},{"key":"747_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199783106.001.0001","volume-title":"Rating scales in Parkinson's disease: clinical practice and research","author":"C Sampaio","year":"2012","unstructured":"Sampaio C, Goetz CG, Schrag A. Rating scales in Parkinson\u2019s disease: clinical practice and research. Oxford: Oxford University Press; 2012."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00747-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00747-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00747-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:54:28Z","timestamp":1757170468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00747-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["747"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00747-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicola Williamson, Thomas Morel, and Milton Biagioni are employees and shareholders of UCB Pharma. Aoife Lydon, Molly Clifford, and Helena Bradley are employees of Adelphi Values Ltd, a health outcomes agency who were paid by UCB Pharma for the conduct of this research. Patrick Cronin was an employee of Adelphi Values Ltd at the time of this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval and oversight was provided by WCG IRB (tracking number: 20223101). Approval notices were received in June 2022. This study was designed and conducted in line with principles outlined in the Declaration of Helsinki and Good Clinical Practice guidelines. All PwP and clinicians provided written informed consent prior to commencement of study-related activities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}